Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23386506 | 0.86 | S1PR4 (0.37) | KDM1A | |
| SCHEMBL23480811 | 0.81 | SPR (0.31) | — | |
| SCHEMBL17542298 | 0.80 | KDM1A (0.44) | KDM1ASIGMAR1KDM4CMCL1MAP3K14 | |
| SCHEMBL17542359 | 0.80 | KDM1A (0.44) | KDM1ASIGMAR1KDM4CMCL1MAP3K14 | |
| SCHEMBL17542361 | 0.80 | KDM1A (0.44) | KDM1ASIGMAR1KDM4CMCL1MAP3K14 | |
| SCHEMBL23442105 | 0.79 | KDM1A (0.39) | KDM1ASIGMAR1KDM4CMCL1 | |
| SCHEMBL25643128 | 0.78 | S1PR4 (0.36) | KDM1A | |
| SCHEMBL23480814 | 0.76 | — | — | |
| SCHEMBL30261908 | 0.74 | KDM1A (0.35) | KDM1ASIGMAR1 | |
| SCHEMBL26194443 | 0.73 | KDM1A (0.45) | KDM1ASIGMAR1KDM4CMAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348494-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11667652-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667652-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210171543-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171543-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | KDM1A 1683/4885SIGMAR1 3384/4885KDM4C 3737/4885 |
| US-20230348494-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | KDM1A 1683/4885SIGMAR1 3384/4885KDM4C 3737/4885 |
| US-11667652-B2 | MCL1 inhibitors | MCL1, BCL2L1, BCLAF1 | KDM1A 1683/4885SIGMAR1 3384/4885KDM4C 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.